A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience

A rating scale has been developed to provide a quantitative estimate of clinical status and disease progression in amyotrophic lateral sclerosis (ALS). This scale includes assessment of swallowing, speech, and respiratory function, and both strength and function of upper and lower extremity musculature. The evaluation is relatively simple to perform and yields reproducible data for both a total ALS score and a score for each group of functions tested. A score of 30 points is normal; 164 points indicates maximal dysfunction. The total ALS score increased in a linear fashion in each of 74 patients followed for at least one year. Among patients, the rate of disease progression varied twenty‐fold, with a continuous distribution from the slowest to most rapid course. Thirty‐four percent of patients exhibited a rapid change of greater than 48 points in the year, predicting progression to a terminal stage in less than two years; 19% of patients exhibited a slow change of less than 13 points in one year, predicting progression to a terminal stage over at least five years. This ALS scoring system should permit more accurate assessment of drug efficacy in clinical trials ánd correlation of rates of progression with clinical variables.

[1]  T L Munsat,et al.  Quantitative motor assessment in amyotrophic lateral sclerosis , 1986, Neurology.

[2]  S. Appel,et al.  Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations. , 1986, Archives of neurology.

[3]  R. Langton-Hewer,et al.  Motor neurone disease: can we do better? A study of 42 patients. , 1984, British medical journal.

[4]  V. Rivera,et al.  Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. , 1980, Archives of neurology.

[5]  H. R. Tyler,et al.  Double‐blind study of modified neurotoxin in motor neuron disease , 1979, Neurology.

[6]  Mulder Dw,et al.  Patient resistance and prognosis in amyotrophic lateral sclerosis. , 1976 .

[7]  F. Norris,et al.  The administration of guanidine in amyotrophic lateral sclerosis , 1974, Neurology.

[8]  J. Brody,et al.  Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam. , 1974, Archives of neurology.

[9]  Olarte Mr Therapeutic trials in amyotrophic lateral sclerosis. , 1982 .

[10]  Schoenberg Bs Controlled therapeutic trials in motor neuron disease: methodologic considerations. , 1982 .

[11]  B. Schoenberg Controlled therapeutic trials in motor neuron disease: methodologic considerations. , 1982, Advances in neurology.

[12]  M. Olarte Therapeutic trials in amyotrophic lateral sclerosis. , 1982, Advances in neurology.

[13]  M. Olarte,et al.  Methodological considerations for clinical trials in motor neuron disease. , 1982, Advances in neurology.

[14]  Y. Yamamura,et al.  Effect of food restriction and its withdrawal on the circadian adrenocortical rhythm in rats under constant dark or constant lighting condition. , 1979, Neuroendocrinology.

[15]  D. W. Mulder,et al.  Patient resistance and prognosis in amyotrophic lateral sclerosis. , 1976, Mayo Clinic proceedings.

[16]  April AIDS TO THE INVESTIGATION OF PERIPHERAL NERVE INJURIES , 1943 .